Vaderis Therapeutics
Tracked across 1 events · 8 articles · First seen Aug 11, 2026 · Last active Aug 11, 2026
Live sentiment trends, attention charts, and prominence tracking available on the
Ergen Dashboard
Business
Impact: Vaderis closed a $152M Series B and initiated its Phase 3 HEROIC study, marking a pivotal transition. The funding extends its runway through potential U.S. approval of engasertib, enhancing its prospects as a first-in-class HHT therapy.
Aug 11, 2026 · 8 articles
ERGEN INTELLIGENCE
Track Vaderis Therapeutics live
Set up alerts, explore relationships, view sentiment trends, and monitor how events impact this entity in real time.
Open Dashboard